ANDA litigation has become almost a more specialized subset of patent law that focuses on the filings of new drug applications and the statutorily infringing abbreviated new drug applications. Recently, Congress has enacted the BPCIA which creates a similar scheme to the laws regulating ANDA litigations for biological products. This presentation will discuss this new abbreviated pathway for biosimilars and try to elaborate on the steps to the BPCIA patent dance.

Is the BPCIA the new ANDA?

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.